Targeted Therapy of Respiratory Syncytial Virus by 2_5A Antisense

Author： Cramer Hagen   Okicki James   Kuang Mei   Xu Zan  

Publisher： Taylor & Francis Ltd

ISSN： 1525-7770

Source： Nucleosides, Nucleotides & Nucleic Acids, Vol.24, Iss.5-7, 2005-04, pp. : 497-501

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antisense approaches for inhibiting respiratory syncytial virus

By Cramer Hagen  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 2, 2005-02 ,pp. : 207-220

Informa Healthcare

Access to resources Recommend Favorite

Carriers for the delivery of a vaccine against respiratory syncytial virus

By Cranage Martin   Taylor Geraldine  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 7, 2005-07 ,pp. : 939-952

Informa Healthcare

Access to resources Recommend Favorite

Motavizumab for the prevention of respiratory syncytial virus infection in infants

By Gill Michelle A   Welliver Robert C  

Expert Opinion on Biological Therapy, Vol. 9, Iss. 10, 2009-10 ,pp. : 1335-1345

Informa Healthcare

Access to resources Recommend Favorite

Palivizumab in the prevention of respiratory syncytial virus disease

By Krilov Leonard R  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 763-769

Informa Healthcare

Access to resources Recommend Favorite

A review of palivizumab and emerging therapies for respiratory syncytial virus

By Shadman Kristin A   Wald Ellen R  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 11, 2011-11 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite